TORONTO, ON–(Marketwired – October 27, 2016) –
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (OTCQX: TITXF) is pleased to announce that the over-allotment option (the “Over-Allotment Option“) granted to the Agents (as defined below) in connection with the Company’s offering of 17,083,333 units (each, a “Unit“) at a price of CDN $0.60 per Unit (the “Offering Price“) completed on September 20, 2016 (the “Closing Date“), has been partially exercised, and the Company has sold an additional 2,030,000 Units at the Offering Price for additional gross proceeds to Titan of CDN $1,218,000. The closing of the Over-Allotment Option earlier today brings the aggregate gross proceeds to Titan under the offering (the “Offering“) to CDN $11,468,000.
Each Unit consists of one common share (each, a “Share“) of the Company and one common share purchase warrant (each, a “Warrant“). Each whole Warrant entitles the holder thereof to acquire one Share of the Company at an exercise price of CDN $0.75 for a period of 60 months following the Closing Date (as defined above). The Shares are listed and posted for trading on the Toronto Stock Exchange (the “TSX“) under the symbol TMD. The Warrants are listed and posted for trading on the TSX under the symbol TMD.WT.I.
The sale of the Units under the Offering and the Over-allotment Option were qualified for sale by way of a prospectus supplement dated September 13, 2016 to the Company’s short form base shelf prospectus dated August 18, 2015 (together, the “Prospectus“), which has been filed in the Provinces of British Columbia, Alberta and Ontario.
Bloom Burton & Co. Limited and Echelon Wealth Partners Inc. (collectively, the “Agents“) acted as agents and Roth Capital Partners acted as special selling group member in connection with the Offering.
For further details regarding the Offering, please see the Company’s press releases dated September 8, 2016, September 9, 2016, September 13, 2016, September 20, 2016, the agency agreement dated September 13, 2016 between the Agents and the Company, and the Prospectus, copies of which are available under the Company’s profile at www.sedar.com.
The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“), or any state securities laws, and accordingly, may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. persons,” as such term is defined in Regulation S promulgated under the U.S. Securities Act (“U.S. Persons“), except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the Company’s securities to, or for the account or benefit of, persons in the United States or U.S. Persons.
About Titan Medical Inc.
Titan Medical Inc. (TSX: TMD) (OTCQX: TITXF) is a Canadian public company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS“). The Company’s SPORT™ Surgical System, currently under development, includes a surgeon-controlled robotic platform that incorporates a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures through a single incision. The surgical system also includes a surgeon workstation that provides a surgeon with an advanced ergonomic interface to the robotic platform for controlling the instruments and provides a 3D high-definition endoscopic view of inside a patient’s body. The SPORT™ Surgical System is designed to enable surgeons to perform a broad set of surgical procedures for general abdominal, gynecologic, and urologic indications. For more information, visit the Company’s website at www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Information Form dated March 30, 2016 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.
Titan Medical Inc.
John E. Barker
Interim Chief Executive Officer
(416) 548-7522 x 151
[email protected]
www.titanmedicalinc.com
EVC Group, Inc.
Amanda Prior
[email protected]
Michael Polyviou
[email protected]
(646) 445-4800
